Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN reported. Those medications include semaglutide (Ozempic and Wegovy) and ...

GLP-1 stands for glucagon-like peptide-1, a satiety hormone the body produces when we eat to help stimulate digestion and ...

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access ...

For adults with diabetes and obesity, GLP-1 RAs are associated with a reduced risk for obesity-related cancer compared with DPP-4 inhibitors.

these findings reinforce growing evidence that dual GIP/GLP-1 receptor agonists like tirzepatide may offer significant metabolic benefits. In addition to supporting access to Zepbound® via ...

CHERRY HILL, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- New data from digital marketing agency Sagapixel reveals that public interest in the term “GLP-1” has officially surpassed search volume for ...

Lixisenatide requires daily injections, while newer GLP-1-targeting drugs like Ozempic and Wegovy, as well as Eli Lilly’s tirzepatide-based Mounjaro and Zepbound, only need to be given once a ...

A federal deadline ending the sale of compounded semaglutide (Ozempic, Wegovy) is now in effect after a similar one for ...

Foods high in protein, fiber, and healthy fats can trigger the release of GLP-1, an important hormone that helps regulate blood sugar levels and promotes a feeling of fullness. Glucagon-like ...